Heartflow, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Heartflow officer Vikram Verghese plans to sell 27,540 shares, valued at $1.37M, under Rule 144. He previously sold 5,876 shares for $297,325.60. Heartflow had 86.95M shares outstanding as of September 3, 2026.
HeartFlow Inc (HTFL) hit an all-time high of $51.26, with a 1-year return of 61.22% and a 6-month return of 110%. The company reported Q2 2026 earnings, with revenue of $64.1M, up 48% YoY, and adjusted loss of $0.07 per share, beating estimates. Stifel raised its price target to $45.00, maintaining a Buy rating.
Farquhar John C.M. (Chief Executive Officer) sold 27,230 shares of Heartflow, Inc. (HTFL) at $50.00 ($1.36M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 2 news stories mentioning HTFL (Heartflow, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent HTFL coverage spans earnings, insider activity and financial news.
In the last 30 days, HTFL insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($4.5M). The most active reporter was Farquhar John C.M., Chief Executive Officer, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale adds modest supply and may exert slight downward pressure on HTFL price.
Positive earnings surprise may drive short-term upside.
Large insider sale may signal reduced confidence, potentially pressuring the stock.
Insider sale may signal reduced confidence or portfolio rebalancing, modest negative pressure on the stock.
Guidance lift signals stronger demand and improved margins, likely supporting a price rally.
alphai scores every news story that mentions HTFL with an AI model for sentiment and relevance, and aggregates insider trades from Heartflow, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Heartflow officer Vikram Verghese plans to sell 27,540 shares, valued at $1.37M, under Rule 144. He previously sold 5,876 shares for $297,325.60. Heartflow had 86.95M shares outstanding as of September 3, 2026.
1 min readHeartFlow Inc (HTFL) hit an all-time high of $51.26, with a 1-year return of 61.22% and a 6-month return of 110%. The company reported Q2 2026 earnings, with revenue of $64.1M, up 48% YoY, and adjusted loss of $0.07 per share, beating estimates. Stifel raised its price target to $45.00, maintaining a Buy rating.
2 min readFarquhar John C.M. (Chief Executive Officer) sold 27,230 shares of Heartflow, Inc. (HTFL) at $50.00 ($1.36M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readFarquhar John C.M. (Chief Executive Officer) sold 32,676 shares of Heartflow, Inc. (HTFL) at $45.00 ($1.47M total) on 2026-08-18 under a Rule 10b5-1 trading plan.
1 min readHeartFlow (HTFL) shares rose after the company raised its full-year revenue targets. Revenue grew 48% YoY to $64.1M in Q2, with adjusted gross margin increasing to 83.3%. The company now expects 40-42% revenue growth for 2026, up from prior forecasts. CEO John Farquhar cited improved operating leverage and scalability.
2 min readFarquhar John C.M. (Chief Executive Officer) sold 15,560 shares of Heartflow, Inc. (HTFL) at $39.06 ($0.61M total) on 2026-08-14 under a Rule 10b5-1 trading plan.
1 min readHeartflow (HTFL) reported Q2 revenue of $64.1M, up 48% year over year, driven by higher U.S. FFRCT and Plaque case volumes. Gross margin rose to 83.0%. Net operating loss widened to $17.9M. The company raised FY26 revenue guidance to $246M-$250M and adjusted gross margin to about 82%.
4 min readHeartflow Inc. (NASDAQ:HTFL) rose about 46% week-on-week after reporting Q2 revenue up 48% to $64.08 million. Net loss widened to $15.7 million. For 2026, the company raised revenue growth guidance to 40% to 42%, or $246 million to $250 million. Stifel and JPMorgan lifted price targets to $45; Wells Fargo raised to $39.
4 min readSimply Wall St reports analyst fair value for HeartFlow (HTFL) rose from $37.00 to about $42.13 after Q2 results and guidance raised. Multiple firms lifted price targets into the $40 to $45 range, citing Q2 metric beats, higher gross margin expectations, and updates tied to 2026 guidance and product or clinical data. Assumptions include higher revenue growth and net margin.
4 min readHeartFlow (HTFL) shares rose 35.7% to $42.08 in the first full session after earnings. In Q2 2026, revenue was $64.1m (up from $43.4m), while net loss widened to $15.7m. Management lifted full-year revenue guidance to $246m to $250m and non-GAAP gross margin improved to 83.3%.
4 min read
